21 completed, 9 terminated, 7 active not recruiting, 3 recruiting. 38 Phase 1, 13 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 38 | Completed 17, Terminated 8, Active not recruiting 7, Withdrawn 3, Recruiting 2, Not yet recruiting 1 |
| Phase 2 | 13 | Completed 9, Terminated 2, Recruiting 1, Withdrawn 1 |
Follow poly-ICLC: new trials by email Literature Review of poly-ICLC trials Research Report on poly-ICLC
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Cancer Vaccine (PCV) Strategy in Triple Negative Breast Cancer Patients Paclitaxel, Carboplatin, Pembrolizumab - Triple Negative Breast Cancer | Phase 1 | Not yet recruiting | Washington University School of Medicine | 30 | 2026-10-01 | 2026-09-04 |
| Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant Dendritic Cell Tumor Peptide Vaccine, Ipilimumab, Leukapheresis - Diffuse Hemispheric Glioma, H3 G34-Mutant | Phase 1 | Withdrawn | Jonsson Comprehensive Cancer Center | 2024-12-01 | 2025-02-24 | |
| A Vaccine (Neoantigen-Targeted ppDC) for the Treatment of H3 G34-mutant Diffuse Hemispheric Glioma Biospecimen Collection, Dendritic Cell Therapy, Leukapheresis - Diffuse Hemispheric Glioma, H3 G34-Mutant | Phase 1 | Active not recruiting | Jonsson Comprehensive Cancer Center | 6 | 2024-06-14 | 2026-02-17 |
| Prototype DAA/TAA Vaccine Targeting MUC1 for Immune Interception and Prevention in Ductal Carcinoma In Situ MUC1 Peptide Vaccine, Hiltonol®, Aromatase Inhibitor - Ductal Carcinoma in Situ | Phase 1 | Recruiting | Finn, Olivera, PhD | 50 | 2024-02-07 | 2026-10-16 |
| ETAPA I: Peptide-based Tumor Associated Antigen Vaccine in GBM Tumor Associated Antigen Peptide Vaccine P30-EPS Vaccine, Hiltonol - Glioma, Malignant | Phase 1 | Active not recruiting | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | 24 | 2023-08-30 | 2026-04-30 |
| In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors Anti-CD40 Agonist Monoclonal Antibody CDX-1140, Poly ICLC, Radiation Therapy - Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Breast Carcinoma | Phase 1 | Active not recruiting | University of Southern California | 14 | 2023-01-09 | 2026-06-18 |
| Neoantigen Vaccines in Pancreatic Cancer in the Window Prior to Surgery Optimized neoantigen synthetic long peptide vaccine, Poly-ICLC - Pancreas Cancer, Pancreatic Cancer | Phase 1 | Completed | Washington University School of Medicine | 33 | 2022-12-15 | 2026-05-06 |
| Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC - Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8 | Phase 1 | Recruiting | Fred Hutchinson Cancer Center | 28 | 2022-06-09 | 2026-07-22 |
| The Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in the Adjuvant Setting. PGV-001, Poly-ICLC, CDX-301 - Prostate Cancer | Phase 1 | Active not recruiting | Ashutosh Kumar Tewari | 27 | 2022-01-05 | 2026-01-07 |
| Neoepitope-based Personalized Vaccine Approach in Pediatric Patients With Recurrent Brain Tumors Personalized peptide vaccine, Poly ICLC, Peripheral blood draw - Pediatric Brain Tumor | Phase 1 | Withdrawn | Washington University School of Medicine | 2021-09-30 | 2021-05-25 | |
| Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer Biopsy Procedure, Biospecimen Collection, Carboplatin - Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma | Phase 2 | Recruiting | National Cancer Institute (NCI) | 86 | 2021-04-13 | 2026-10-13 |
| Neoantigen Peptide Vaccine Strategy in Pancreatic Cancer Patients Following Surgical Resection and Adjuvant Chemotherapy Neoantigen Peptide Vaccine, Poly ICLC, Blood for immune monitoring - Pancreas Cancer, Pancreatic Cancer | Phase 1 | Terminated | Washington University School of Medicine | 12 | 2020-02-13 | 2024-07-17 |
| Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma Dendritic Cell Tumor Cell Lysate Vaccine, Pembrolizumab, Placebo Administration - Recurrent Glioblastoma | Phase 1 | Completed | Jonsson Comprehensive Cancer Center | 46 | 2020-01-08 | 2026-08-31 |
| Personalized Tumor Vaccine Strategy and PD-1 Blockade in Patients With Follicular Lymphoma Personalized tumor vaccine, Poly ICLC, Nivolumab - Follicular Lymphoma | Phase 1 | Terminated | Washington University School of Medicine | 4 | 2018-10-16 | 2023-08-14 |
| A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma NEO-PV-01, Nivolumab, Adjuvant - Metastatic Melanoma | Phase 1 | Terminated | BioNTech US Inc. | 22 | 2018-10-08 | 2020-09-03 |
| A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer NEO-PV-01, Pembrolizumab, Adjuvant - Carcinoma, Non-Small-Cell Lung, Lung Cancer | Phase 1 | Completed | BioNTech US Inc. | 38 | 2018-05-04 | 2021-02-26 |
| DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Poly ICLC, Decitabine, and Nivolumab in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Decitabine, Laboratory Biomarker Analysis - Acute Myeloid Leukemia, Blasts 30 Percent or Less of Bone Marrow Nucleated Cells | Phase 1 | Completed | Roswell Park Cancer Institute | 8 | 2018-03-27 | 2026-02-27 |
| Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma Poly-ICLC, Tumor Treating Fields, Peptides - Glioblastoma | Phase 1 | Active not recruiting | Adilia Hormigo | 13 | 2018-03-01 | 2026-09-21 |
| Pembrolizumab + Poly-ICLC in MRP Colon Cancer pembrolizumab, Poly-ICLC - Metastatic Colon Cancer, Solid Tumor | Phase 1 / Phase 2 | Completed | Asha Nayak | 42 | 2018-01-10 | 2024-06-07 |
| Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Atezolizumab, DEC-205/NY-ESO-1 Fusion Protein CDX-1401, Guadecitabine - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 / Phase 2 | Terminated | National Cancer Institute (NCI) | 9 | 2017-11-08 | 2026-10-20 |
Showing 20 of 44. Sign in to see all of them.
Melanoma (12) · Breast Neoplasms (6) · Carcinoma, Non-Small-Cell Lung (5) · Glioblastoma (5) · Neoplasms (4) · Sarcoma (4) · Lung Neoplasms (3) · Ovarian Neoplasms (3) · Squamous Cell Carcinoma of Head and Neck (3) · Triple Negative Breast Neoplasms (3) · Urinary Bladder Neoplasms (3) · Carcinoma, Merkel Cell (2) · Fallopian Tube Neoplasms (2) · Glioma (2) · Leukemia, Myeloid, Acute (2)
Washington University School of Medicine (6) · BioNTech US Inc. (3) · Jonsson Comprehensive Cancer Center (3) · National Cancer Institute (NCI) (3) · Nina Bhardwaj (3) · Roswell Park Cancer Institute (3) · Adilia Hormigo (1) · Asha Nayak (1) · Ashutosh Kumar Tewari (1) · Case Comprehensive Cancer Center (1) · Celldex Therapeutics (1) · Craig L Slingluff, Jr (1) · Dana-Farber Cancer Institute (1) · Finn, Olivera, PhD (1) · Fred Hutchinson Cancer Center (1)
United States (42) · Hungary (1) · Poland (1) · Russia (1) · Serbia (1) · Spain (1) · Ukraine (1)
Nina Bhardwaj, MD, PhD (5) · Mark DeMario, MD (3) · Elizabeth Griffiths (2) · William E Gillanders, M.D. (2) · Adilia Hormigo, MD, PhD (1) · Anthony C Wang (1) · Anthony C Wang, MD (1) · Asha Nayak, MD (1) · Ashutosh Tewari, MD (1) · Craig L Slingluff, Jr., MD (1) · Dara Lundon, MD MSc MBA PhD (1) · David A. Reardon, MD (1) · David H Smith, MD (1) · Delva Deauna-Limayo, MD (1) · Emese Zsiros, MD (1)
PMID 24739759, PMID 24792486, PMID 24801836, PMID 24888813, PMID 29157306, PMID 29950349, PMID 33064988, PMID 33294862, PMID 33479501, PMID 34311780, PMID 35121932, PMID 38713894, PMID 40809194
P30CA016056 (2), 2016 (1), P30CA015704 (1), P50CA190991 (1), P50CA196510 (1), R21CA233856 (1), R44CA183075 (1), U01CA154967 (1), UM1CA186704 (1)